News
News Center
Jiuzhitang Maker attends the Stem Cell Summit Workshop
2023-04-12
April 7-9, 2023, organized by the China Association for Medical Biotechnology The clinical research workshop on stem cells was successfully held in Beijing.
This is a concentrated showcase of China's current clinical research achievements in stem cells—and also a high-end "academic feast." , aiming to build a communication bridge, foster the exchange of ideas and resources, and jointly drive the high-quality development of clinical stem cell research in our country.
As a leading force in the field of clinical stem cell research and a member organization of the China Association for Medical Biotechnology, Dr. Gao Yansong, General Manager of Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (hereinafter referred to as "Jiuzhitang Maker"), was invited to attend this grand event. Together with officials responsible for the national management of clinical stem cell research, experts in related fields, and representatives from stem cell clinical research institutions, stem cell drug development organizations, as well as fund and investment entities, we jointly studied and discussed China's current achievements in stem cell clinical research.
At the meeting, Dr. Gao Yansong, General Manager of Jiuzhitang Maker Featuring the interim results of the Phase I/IIa study on bone marrow mesenchymal stem cell therapy for ischemic stroke, From approval of clinical trials for imported products, collaborating hospitals and PIs, to the progress of clinical trials, Preliminary safety, preliminary efficacy, Research objectives, study design, inclusion criteria, Studying drug management and risk control Content was shared across various areas, earning unanimous recognition and praise from industry experts.
Jiuzhitang Maker, in collaboration with Beijing Tiantan Hospital affiliated with Capital Medical University, has launched Phase I/IIa Clinical Trial of Stem Cell Therapy for Ischemic Stroke , which has been approved by the Drug Review Center of the National Medical Products Administration The first one Clinical trials using imported stem cells, The first one Clinical trials using bone marrow-derived mesenchymal stem cells are also The first one Clinical trials using stem cells to treat major neurological indications are of significant importance for the development of China's stem cell industry.
Jiuzhitang Maker as Strictly in accordance with the "Good Manufacturing Practice for Pharmaceutical Products" A national high-tech enterprise specializing in the preparation of clinical-grade stem cells that meet Chinese and U.S. pharmaceutical regulatory requirements, equipped with A large-scale stem cell R&D and production facility compliant with cGMP standards in China, the United States, and the European Union. Office and production spaces total approximately 4,800 m², with the production area featuring 4 independent B+A-class units Cleanroom services. Currently, we offer stem cell CQDMO-related services to hospitals, research institutions, and emerging companies, including contract manufacturing, quality testing, quality research, training in quality management systems, and clinical application consulting.
The successful convening of this stem cell clinical research symposium has played a positive and proactive role in deepening basic stem cell research, exploring and developing new clinical treatment technologies in stem cell and regenerative medicine, enhancing the treatment of challenging diseases, and advancing the clinical application of stem cells as well as the growth of the regenerative medicine field. Looking ahead, Jiuzhitang Maker will continue to strengthen its deep collaboration with China's leading Grade-III hospitals. Continuously expanding collaborative opportunities, we strive to generate more groundbreaking scientific achievements in stem cell-based disease therapies, contributing positively to human health.
Related News
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy